XON11 / Xenothera - LARVOL DELTA

XON11, a novel multi-target antibody in pancreas cancer (AACR 2025) - "The aim of these studies was to assess the tolerance and efficacy of XON11 in non-clinical pancreatic cancer models.Material and XON11 ability to induce Complement Dependent Cytotoxicity (CDC) and apoptosis compared to gemcitabine was tested in a panel of human pancreas cancer cell (MiaPaca, Aspc1, Capan, Panc1) after 24h of incubation. Based on its high potency and tolerance, XON11 can provide a novel and promising therapy for fighting recurrent pancreatic cancer."

Oncology • Pancreatic Cancer • Solid Tumor • CASP8 • CASP9 • KRAS